Interferon beta-1b, interferon beta-1a and glatiramer acetate for the treatment of single demyelinating event with clinically isolated syndrome (to be included in a review of TA32 - subject to review proposal consultation)
 
Status Suspended
Process MTA
Referral date 01 July 2009
Topic area
  • Central nervous system

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC

Timeline

Key events during the development of the guidance:

Date Update
1 April 2010

This technology appraisal was formally referred to the Institute as part of the 21st wave work programme. The remit was as follows:

To appraise the clinical and cost effectiveness of interferon beta-1b, interferon beta-1a and glatiramer acetate within their licensed indications for the treatment of single demyelinating event with clinically isolated syndrome (to be included in a review of TA32).

TA32 is currently regarded as ‘static’ guidance and the Institute is of the opinion that this is still appropriate. As a result, this appraisal will not commence at this time due to the remit specifically indicating that it should be included in a review of TA32.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.


For further information on how we develop guidance, please see our page about NICE technology appraisal guidance